Study Evaluating the Safety of MOA-728 Administered Orally to Healthy Subjects

Bausch Health Americas, Inc.48 enrolled

Overview

This is the first multiple-dose experience in humans with MOA-728 in an oral formulation. This study will provide an assessment of the safety, tolerability, and pharmacokinetics (PK) of MOA-728 following administration of ascending multiple oral doses to healthy subjects.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Masking

DOUBLE

Enrollment

Conditions

Postoperative Complications Constipation

Interventions

MOA-728DRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 50 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Healthy men and women

Locations (1)

Unnamed facility

Philadelphia, Pennsylvania, United States

Outcomes

Primary Outcomes

Safety

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.